Dr. James A. Maher JR., MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Virginia Commonwealth University, School of Medicine (1974)
- Years since graduation
- 52
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 329
Licensed in Texas since 1978, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1974Medical school: Virginia Commonwealth University, School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TX license F1131 (first issued 1978; active) · LA license 04775R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Katy Hospital Katy, TX
- Townsen Memorial Hospital Humble, TX
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 329
- Services billed
- 1,230
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 295 | 163 |
| Pathology examination of tissue using a microscope, intermediate complexity | 293 | 93 |
| Special stained specimen slides to identify organisms including interpretation and report | 123 | 47 |
| New patient office or other outpatient visit, 30-44 minutes | 123 | 123 |
| Special stained specimen slides to examine tissue including interpretation and report | 122 | 47 |
| Biopsy of large bowel using a flexible endoscope | 91 | 90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 84 | 83 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 47 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 46 | 45 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Houston, TX | 319 |
| Omeprazole Other prescribers in Houston, TX | 123 |
| Sutab (sod sulf/pot chloride/mag sulf) | 81 |
| Xifaxan (rifaximin) Other prescribers in Houston, TX | 34 |
| Ursodiol Other prescribers in Houston, TX | 26 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Houston, TX | 23 |
| Mesalamine Other prescribers in Houston, TX | 21 |
| Lactulose Other prescribers in Houston, TX | 15 |
| Ondansetron Hcl Other prescribers in Houston, TX | 14 |
| Metronidazole Other prescribers in Houston, TX | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 31 payments worth $553 in total to this clinician.
| Pfizer Inc. | $165 |
|---|---|
| Phathom Pharmaceuticals, Inc. | $84.76 |
| AbbVie Inc. | $77.38 |
| Janssen Biotech, Inc. | $67.62 |
| Lilly USA, LLC | $54.63 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.73 |
| Ipsen Biopharmaceuticals, Inc | $42.84 |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.69 |
| Food and Beverage | $553 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $281,904 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - Roche Cancer Screening Collection Study
Genentech, Inc. - Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presume…
Boehringer Ingelheim International GmbH - Evaluating the safety and efficacy of tradipitant vs. placebo in idiopathic and diabetic gastroparesis
Vanda Pharmaceuticals Inc. - A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · Recruiting · NCT07165028 - Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04530123 - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - A multicenter prospective noninterventional study of realworld effectiveness of etrasimod in patients with ulcerative colitis endeavouruc
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.